Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1968 3
1969 1
1988 1
1989 1
1990 1
1995 1
1996 1
2000 1
2001 3
2002 2
2005 2
2007 2
2008 1
2009 1
2010 1
2011 2
2012 4
2013 5
2014 2
2015 1
2016 3
2017 2
2018 5
2019 1
2020 1
2021 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

48 results
Results by year
Filters applied: . Clear all
Page 1
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.
Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, Hsieh W, Sanchez-Vega F, Brown DN, Da Cruz Paula AF, Morris L, Selenica P, Eichenberger E, Shen R, Schultz N, Rosen N, Scaltriti M, Brogi E, Baselga J, Reis-Filho JS, Chandarlapaty S. Li Z, et al. Among authors: toy w. Cancer Cell. 2018 Dec 10;34(6):893-905.e8. doi: 10.1016/j.ccell.2018.11.006. Cancer Cell. 2018. PMID: 30537512 Free PMC article.
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors.
Razavi P, Dickler MN, Shah PD, Toy W, Brown DN, Won HH, Li BT, Shen R, Vasan N, Modi S, Jhaveri K, Caravella BA, Patil S, Selenica P, Zamora S, Cowan AM, Comen E, Singh A, Covey A, Berger MF, Hudis CA, Norton L, Nagy RJ, Odegaard JI, Lanman RB, Solit DB, Robson ME, Lacouture ME, Brogi E, Reis-Filho JS, Moynahan ME, Scaltriti M, Chandarlapaty S. Razavi P, et al. Among authors: toy w. Nat Cancer. 2020 Apr;1(4):382-393. doi: 10.1038/s43018-020-0047-1. Epub 2020 Mar 23. Nat Cancer. 2020. PMID: 32864625 Free PMC article.
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.
Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, Hudis C, Chen D, Taran T, Hortobagyi G, Greene G, Berger M, Baselga J, Chandarlapaty S. Toy W, et al. Nat Genet. 2013 Dec;45(12):1439-45. doi: 10.1038/ng.2822. Epub 2013 Nov 3. Nat Genet. 2013. PMID: 24185512 Free PMC article.
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.
Toy W, Weir H, Razavi P, Lawson M, Goeppert AU, Mazzola AM, Smith A, Wilson J, Morrow C, Wong WL, De Stanchina E, Carlson KE, Martin TS, Uddin S, Li Z, Fanning S, Katzenellenbogen JA, Greene G, Baselga J, Chandarlapaty S. Toy W, et al. Cancer Discov. 2017 Mar;7(3):277-287. doi: 10.1158/2159-8290.CD-15-1523. Epub 2016 Dec 16. Cancer Discov. 2017. PMID: 27986707 Free PMC article.
Viewpoint.
Toy WJ. Toy WJ. UNA Nurs J. 1967 Feb;65:38. UNA Nurs J. 1967. PMID: 5181508 No abstract available.
Defining the Energetic Basis for a Conformational Switch Mediating Ligand-Independent Activation of Mutant Estrogen Receptors in Breast Cancer.
Mayne CG, Toy W, Carlson KE, Bhatt T, Fanning SW, Greene GL, Katzenellenbogen BS, Chandarlapaty S, Katzenellenbogen JA, Tajkhorshid E. Mayne CG, et al. Among authors: toy w. Mol Cancer Res. 2021 Sep;19(9):1559-1570. doi: 10.1158/1541-7786.MCR-20-1017. Epub 2021 May 21. Mol Cancer Res. 2021. PMID: 34021071 Free PMC article.
Novel breast cancer metastasis-associated proteins.
Ho J, Kong JW, Choong LY, Loh MC, Toy W, Chong PK, Wong CH, Wong CY, Shah N, Lim YP. Ho J, et al. Among authors: toy w. J Proteome Res. 2009 Feb;8(2):583-94. doi: 10.1021/pr8007368. J Proteome Res. 2009. PMID: 19086899
The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells.
Fanning SW, Jeselsohn R, Dharmarajan V, Mayne CG, Karimi M, Buchwalter G, Houtman R, Toy W, Fowler CE, Han R, Lainé M, Carlson KE, Martin TA, Nowak J, Nwachukwu JC, Hosfield DJ, Chandarlapaty S, Tajkhorshid E, Nettles KW, Griffin PR, Shen Y, Katzenellenbogen JA, Brown M, Greene GL. Fanning SW, et al. Among authors: toy w. Elife. 2018 Nov 29;7:e37161. doi: 10.7554/eLife.37161. Elife. 2018. PMID: 30489256 Free PMC article.
48 results